4月1日 - ** 药物开发商伊顿制药ETON.O股价下跌约3%，至12.58美元
** ETON称 (link)，该公司已将其罕见病药物Increlex的非美国商业权利授权给西班牙 Esteve制药公司。
** Esteve将向ETON支付400万欧元(432万美元)，获得长达10年的许可权。
** ETON 仍将生产该产品并以固定价格出售给 Esteve
** 埃斯特韦公司还可选择在未来以高达600万欧元的价格永久获得该产品的国际销售权。
** Increlex 用于治疗患有严重原发性胰岛素样生长因子-1 缺乏症的儿童和青少年的生长迟缓。
** 包括盘中走势在内，ETON今年累计下跌2.6
(1 美元 = 0.9267 欧元)
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.